http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Pitakkarnkul, Supakorn (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Pitakkarnkul, Supakorn,Tangjitgamol, Siriwan,Srijaipracharoen, Sunamchok,Manusirivithaya, Sumonmal,Pataradool, Kamol,Prutthiphongsit, Watchara,Khunnarong, Jakkapan,Thavaramara, Thaovalai Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.4
Background: To study the response rate, toxicity profiles, and survival of refractory or recurrent epithelial ovarian cancer (EOC) patients treated with paclitaxel. Materials and Methods: Patients with refractory or recurrent EOC who were treated with paclitaxel between January 2002 and December 2011 at the Department of Obstetrics and Gynecology, Faculty of Medicine, Vajira Hospital were identified. Clinicopathological features of the patients including detailed data of paclitaxel treatment were collected. Results: During the study period, a total of 44 patients were identified, with a mean age of $52.9{\pm}8.2$ years. Some 13.6% (six patients) had refractory cancer to first-line chemotherapy while 86.4% (38 patients) had recurrent cancer. Among these, 35 (79.6%) and 9 (20.4%) patients were considered as platinum-sensitive and platinum-resistant, respectively. Three patients (6.8%) received fewer than 2 cycles of paclitaxel due to loss to follow-up, leaving 41 patients evaluable for response. The overall response rate observed in all 41 patients was 41.5% (17 patients; 12 complete and five partial responses): 12.5% or 1/8 patients with refractory or platinum-resistant cancer and 48.5% or 16/33 patients with platinum-sensitive disease. Stable disease was demonstrated in 17.0% (seven patients) while progressive disease was apparent in 41.5% (17 patients). Median time to progress was 4.5 months (range, 0.67-58.6 months). Median progression-free survival was not reached while median overall survival was 16.3 months (95% confidence interval, 11.0 months -21.6 months). Common toxicities were neutropenia, neuropathy, and alopecia. Conclusions: Paclitaxel is an active agent for refractory or recurrent EOC. Neutropenia, neuropathy and alopecia are common side effects.
-
Management of inoperable endometrial cancer
Supakorn Pitakkarnkul,Saranya Chanpanitkitchot,Siriwan Tangjitgamol 대한산부인과학회 2022 Obstetrics & Gynecology Science Vol.65 No.4
영어 Some endometrial cancer (EMC) patients are not good candidates for primary surgery. The three major types oftreatment for inoperable EMC are radiation therapy, chemotherapy, or their combination as neoadjuvant treatmentbefore surgery. Radiation therapy alone (of different modes) has been used as the sole definitive therapeuticmodality, particularly for early-stage disease that is limited to the uterine body and cervix with or without parametrialinvasion. The most common treatment modality is neoadjuvant treatment before surgery. Postoperative adjuvanttreatment is also occasionally used, depending mainly on the sites of the disease and the results of surgery. Data onneoadjuvant hormonal or radiation therapy are limited, with studies focusing on laboratory outcomes or havingonly a small number of patients. Most neoadjuvant treatments before surgery involved chemotherapy and fewercombined chemoradiotherapy. Surgery was generally performed, particularly in patients who had shown responses orat least stable disease to neoadjuvant treatment. Perioperative outcomes after neoadjuvant treatment were superiorto those after primary surgery, whereas survival data were still inconsistent. Features that had or tended to have afavorable prognosis were younger age, early-stage disease, response to neoadjuvant treatment, low preoperativecancer antigen-125 level, and optimal surgery. Among different modalities of neoadjuvant treatment, which hasbecome a frequent mode of treatment, neoadjuvant chemotherapy was more common than radiation therapy aloneor chemoradiation.
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
